By Chris Wack
Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk.
Shares of the Ann Arbor, Mich., company are up 120% in the past 12 months.
Nexletol and Nexlizet are indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy.
Nexlizet, alone or in combination with other LDL-C lowering therapies, will reduce LDL-C in adults with primary hyperlipidemia. Nexletol, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy isn't possible, will reduce LDL-C in adults with primary hyperlipidemia.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 02, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。